Notice of Annual General Meeting of Vitrolife AB (publ)
The Annual General Meeting of Vitrolife AB (publ) will take place on Tuesday April 28, 2020, at 4.30 p.m. at Elite Park Avenue Hotel, Kungsportsavenyen 36-38 in Gothenburg. Notice of attendance at the Annual General Meeting shall be given no later than Wednesday, April 22, 2020.
Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83 or by e-mail firstname.lastname@example.org. Full name/business name, preferably personal identification number/ company registration number (or the equivalent), address, telephone number, number of shares, details of any advisors and where appropriate details of a representative or proxy must be stated in the notification. A proxy form in Swedish for shareholders wishing to be represented by proxy will be found on www.vitrolife.com.
Shareholders that have their shares registered in the name of a nominee must temporarily record their shares in the share register kept by Euroclear Sweden AB in their own names to be able to attend the General Meeting.
The following proposals will be amongst those presented at the Annual General Meeting:
- Dividend of SEK 1.05 per share and Thursday, April 30, 2020, as the record date for the dividend.
- The Election Committee proposes that the Board shall consist of five members. The Election Committee proposes re-election of the Board members Lars Holmqvist, Pia Marions, Henrik Blomquist and Jón Sigurdsson and election of new Board member Karen Lykke Sorensen. It is proposed that Jón Sigurdsson is re-elected as Chairman of the Board. Remuneration to the Board members is proposed to be SEK 2,165,000, of which SEK 825,000 to the Chairman of the Board, SEK 275,000 to each of the other members of the Board. SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to the Chairman of the Remuneration Committee and SEK 30,000 to the other members of these committees. The proposal means that the Board fees are unchanged compared to the previous year.
- Authorization for the Board to resolve to issue new shares up until the next Annual General Meeting.
- Authorization for the Board to resolve on acquisition of the company’s own shares during the period up until the next Annual General Meeting.
The Public Health Agency of Sweden has upgraded the risk level for the spread of the new coronavirus in Sweden. Due to the uncertainty surrounding the coronavirus, a decision has been made to take a number of precautionary measures regarding the Annual General Meeting. Vitrolife is following the development of events very carefully and will give information about precautionary measures ahead of the Annual General Meeting on the website. Everyone intending to attend the Annual General Meeting is requested to keep themselves updated via www.vitrolife.com.
Attachment: Full notice
Gothenburg, March 24, 2020
VITROLIFE AB (publ)
Jón Sigurdsson, Chairman of the Board, email: email@example.com
Mikael Engblom, CFO, phone 46 31 721 80 14
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 4.30 pm CET on March 24, 2020.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.
Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com/